Skip to main content

Table 1 Study parameters

From: Cost-effectiveness analysis of a strategy to delay progression to dialysis and death among chronic kidney disease patients in Lima, Peru

Survival projection

Value

Sensitivity range

Source

Dialysis (probability C2D)

 Treatment effect (hazard ratio)

0.42

0.21–0.71

Bravo-Zúñiga et al. [8]

 Lambdaa

0.008

0.007–0.009

Estimated

 Gammaa

0.938

0.925–0.952

Estimated

Mortality (probability C2Dth)

 Treatment effect (hazard ratio)

1

0.88–1.13

Bravo-Zúñiga et al. [8]

 Lambdaa

0.043

0.034–0.053

Estimated

 Gammaa

1.143

1.098–1.193

Estimated

Mortality among dialysis patients (probability D2Dth)

0.05

 

Cieza-Zevallos et al. [14]

Annual costs (USD)b

  

Estimated (see Table 2)

 RHP cost of treatment

531

452–611

 

 Standard of care cost of treatment

45

38–52

 

 Dialysis treatment

13,459

11,440–15,478

 

 RHP Initial investment (one-time)

30,412

  

 RHP annual operational costs

4995

  

Utility scores

  

Go et al. [16]

 CKD event-free

0.84

0.76–0.92

 

 First time dialysis

0.65

0.59–0.72

 

General

 Discount rate costs and outcomes (%)

3

0–5

 

 Exchange rate (PEN per USD)

3.3

 

Central Reserve Bank of Peru [17]

 Projection length (cycles)

30

  

 Cycle length (years)

1

  
  1. RHP Renal Health Program; CKD chronic kidney disease; USD United States Dollars; PEN Peruvian Soles
  2. aValues rounded to the third decimal
  3. bAll costing data was rounded to the closest integer